Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Ltd. Submits Pre-IND Meeting Request to the US FDA for its Gout Drug Candidate, REV-002

Marketwired April 30, 2014

Revive Therapeutics Ltd. Announces Results for the Three and Six Months Ended December 31, 2013

Marketwired February 27, 2014

Revive Therapeutics Ltd. Signs Material Transfer Agreement with Japanese Pharmaceutical Company

Marketwired February 20, 2014

Revive Therapeutics Ltd. Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression

Marketwired February 12, 2014

Revive Therapeutics Ltd. Grants Incentive Stock Options

Marketwired February 3, 2014

Revive Therapeutics Ltd. Announces Initiation of A Phase 2a Study of REV-001 (Tianeptine) for the Prevention of Opioid-Induced Respiratory Depression

Marketwired January 15, 2014

Revive Therapeutics Ltd. Begins Trading on TSX Venture Exchange Under the Symbol RVV

Marketwired January 8, 2014

Mercury Capital II Limited Announces Closing of Qualifying Transaction With Revive Therapeutics Inc.

Marketwired January 6, 2014

Mercury Capital II Limited Enters Into Definitive Agreement and Files Filing Statement on Sedar in Connection with Proposed Qualifying Transaction with Revive Therapeutics Inc.

Marketwired November 27, 2013